Palbociclib in the Treatment of Recurrent or Stage 4 Head and Neck Cancer

ASCO 2018 Congress featured among its noteworthy developments in head and neck cancers a study of metastatic or recurrent, HPV-related -negative head and neck cancers treated with a new CDK 4/6-inhibiting cancer drug, palbociclib (Ibrance), in a phase-2 clinical trial .
In Western societies, nearly half of head and neck cancers are associated with HPV infection. This study enrolled patients with recurrent or metastatic cancers unrelated to HPV, for which smoking and alcohol use are the main risk factors. HPV-unrelated head and neck cancers are known to have a poorer prognosis (disease course) and shorter survival.
Cell division has control mechanisms, one being the CDK 4/6 system. Because cancer cells divide very frequently, the idea arose that drugs acting on cell division checkpoints could treat cancer, and new CDK 4/6 inhibitors were developed. All drugs of this type approved for hormone-positive Her2-negative breast cancertotal 3: palbociclib (Ibrance), ribociclib (Kisqali) and abemaciclib (Verzenio). Among them, palbociclibwas the first CDK 4/6 inhibitor developed.

Laboratory research showed that, in head and neck cancer, commonly used cetuximab (Erbitux) and similar EGFR inhibitorscan encounter resistanceinvolving the CDK 4/6 system. This suggested palbociclib could reverse cetuximab resistance.
The clinical trial enrolled previously cisplatin-treated patients with recurrent or metastatic squamous, HPV-unrelated head and neck cancer, totaling 30 patients. They received weekly intravenous cetuximab with oral palbociclib.
Study Results;
- The 30 patients had a median age of 67.
- Among patients, %35 responded (of the 23 evaluable to date, 8). A total of 3 had a complete response.
- Median progression-free survival (duration of disease control with treatment) was 6.4 months, and median overall survival was 12.1 months.
- Before study entry, 3 patients, and after the study, eight, received immunotherapy .
Conclusion / Comment
Remembering that median overall survival with cetuximab alone is approximately 6 months in recurrent or metastatic, platinum-resistant head and neck cancer, adding palbociclib and increasing this to 12.1 months was very positively received in oncology. Median overall survival of 12.1 months is the longest reported to date for platinum-resistant recurrent-metastatic squamous head and neck cancer. As a phase-2 study, it is not yet strong enough to change routine clinical practice, but the benefit in cisplatin-resistant patients is clear. We will await and share results of large randomized trials of CDK 4/6 inhibitors.
Sources
Multicenter phase II trial of palbociclib, a selective cyclin dependent kinase (CDK) 4/6 inhibitor, and cetuximab in platinum-resistant HPV unrelated (-) recurrent/metastatic head and neck squamous cell carcinoma (RM HNSCC).
2018 ASCO Annual Meeting - Abstract No: 6008
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.